|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
selenocystine results in increased expression of BAX protein |
CTD |
PMID:35863474 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
selenocystine results in decreased expression of BCL2 protein |
CTD |
PMID:35863474 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [selenocystine results in decreased expression of CASP3 protein] |
CTD |
PMID:35863474 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
selenocystine results in decreased expression of CASP8 protein |
CTD |
PMID:35863474 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
selenocystine results in decreased expression of CASP9 protein |
CTD |
PMID:35863474 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
selenocystine results in decreased expression of CAT protein |
CTD |
PMID:35863474 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Dclre1c |
DNA cross-link repair 1C |
decreases expression |
ISO |
selenocystine results in decreased expression of DCLRE1C protein |
CTD |
PMID:39461470 |
|
NCBI chr17:74,775,828...74,810,089
Ensembl chr17:74,776,935...74,809,186
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
NFE2L2 mutant form inhibits the reaction [selenocystine results in increased expression of GCLC mRNA] |
CTD |
PMID:22807314 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions increases expression |
ISO |
selenocystine results in increased phosphorylation of H2AX protein [selenocystine co-treated with Cisplatin] results in increased expression of H2AX protein; Cisplatin promotes the reaction [selenocystine results in increased expression of H2AX protein]; selenocystine promotes the reaction [Cisplatin results in increased expression of H2AX protein] |
CTD |
PMID:35863474 PMID:39461470 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Lig4 |
DNA ligase 4 |
decreases expression |
ISO |
selenocystine results in decreased expression of LIG4 protein |
CTD |
PMID:39461470 |
|
NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
selenocystine inhibits the reaction [Methylmercury Compounds results in decreased activity of MAPK1 protein] |
CTD |
PMID:23838314 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
selenocystine inhibits the reaction [Methylmercury Compounds results in decreased activity of MAPK3 protein] |
CTD |
PMID:23838314 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression multiple interactions |
ISO |
selenocystine results in decreased expression of MKI67 protein Cisplatin promotes the reaction [selenocystine results in decreased expression of MKI67 protein]; selenocystine promotes the reaction [Cisplatin results in decreased expression of MKI67 protein] |
CTD |
PMID:39461470 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions affects localization |
ISO |
NFE2L2 mutant form inhibits the reaction [selenocystine results in increased expression of GCLC mRNA]; NFE2L2 mutant form inhibits the reaction [selenocystine results in increased expression of NQO1 mRNA]; NFE2L2 mutant form inhibits the reaction [selenocystine results in increased expression of TXNRD1 mRNA] selenocystine affects the localization of NFE2L2 protein |
CTD |
PMID:22807314 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions affects expression increases expression |
ISO |
NFE2L2 mutant form inhibits the reaction [selenocystine results in increased expression of NQO1 mRNA] selenocystine affects the expression of NQO1 mRNA selenocystine results in increased expression of NQO1 protein |
CTD |
PMID:22807314 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression multiple interactions |
ISO |
selenocystine results in decreased expression of RAD51 protein [Cisplatin co-treated with selenocystine] results in decreased expression of RAD51 protein; selenocystine inhibits the reaction [Cisplatin results in increased expression of RAD51 protein] |
CTD |
PMID:39461470 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
increases uptake |
ISO |
SLC3A1 protein results in increased uptake of selenocystine |
CTD |
PMID:18845132 |
|
NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:9,608,178...9,641,907
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
selenocystine results in decreased expression of SOD1 protein |
CTD |
PMID:35863474 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
selenocystine results in decreased expression of SOD2 protein |
CTD |
PMID:35863474 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases response to substance multiple interactions increases expression |
ISO |
TXNRD1 protein results in decreased susceptibility to selenocystine NFE2L2 mutant form inhibits the reaction [selenocystine results in increased expression of TXNRD1 mRNA] selenocystine results in increased expression of TXNRD1 mRNA; selenocystine results in increased expression of TXNRD1 protein |
CTD |
PMID:20920480 PMID:22807314 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Xpa |
XPA, DNA damage recognition and repair factor |
multiple interactions decreases activity |
ISO |
selenocystine inhibits the reaction [Zinc binds to XPA protein] selenocystine results in decreased activity of XPA protein |
CTD |
PMID:15265038 |
|
NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
decreases expression multiple interactions |
ISO |
selenocystine results in decreased expression of XRCC4 protein [Cisplatin co-treated with selenocystine] results in decreased expression of XRCC4 protein; Cisplatin promotes the reaction [selenocystine results in decreased expression of XRCC4 protein]; selenocystine promotes the reaction [Cisplatin results in decreased expression of XRCC4 protein] |
CTD |
PMID:39461470 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
decreases expression |
ISO |
selenocystine results in decreased expression of XRCC5 protein |
CTD |
PMID:39461470 |
|
NCBI chr 9:73,955,216...74,044,020
Ensembl chr 9:73,955,216...74,044,018
|
|
G |
Xrcc6 |
X-ray repair cross complementing 6 |
multiple interactions decreases expression |
ISO |
selenocystine promotes the reaction [Cisplatin results in decreased expression of XRCC6 protein] selenocystine results in decreased expression of XRCC6 protein |
CTD |
PMID:39461470 |
|
NCBI chr 7:113,542,992...113,563,762
Ensembl chr 7:113,543,057...113,563,762
|
|